Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.
Chronic inflammation associated with the amyloid plaques may represent an acute phase response in the brain. We quantitated the levels of two inflammatory markers; alpha 1-antichymotrypsin (alpha 1-ACT) and interleukin 1 beta (IL-1 beta) in paired serum and cerebrospinal fluid (CSF) samples from 40 patients with Alzheimer's disease (AD), 20 patients with Parkinson's disease (PD), and 42 age-matched controls. No differences in serum or CSF levels of either alpha 1-ACT or IL-1 beta were found between the groups. However, some AD patients had increased alpha 1-ACT index, suggesting an intrathecal production of alpha 1-ACT. Although alpha 1-ACT or IL-1 beta might be involved in the pathogenesis of AD, our results show that their measurement in serum or CSF is not valuable to support the clinical diagnosis of AD.
Pirttila
T
T
Department of Immunology, New York State Institute for Basic Research in Developmental Disabilities, Staten Island 10314.
Mehta
P D
PD
Frey
H
H
Wisniewski
H M
HM
D000368:Aged; D000418:Albumins / Q000134:cerebrospinal fluid / Q000378:metabolism; D000544:Alzheimer Disease / Q000097:blood* / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007375:Interleukin-1 / Q000097:blood* / Q000134:cerebrospinal fluid*; D010300:Parkinson Disease / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism; D000514:alpha 1-Antichymotrypsin / Q000097:blood* / Q000134:cerebrospinal fluid*
D000418:Albumins; D015415:Biomarkers; D007375:Interleukin-1; D000514:alpha 1-Antichymotrypsin